AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29284737 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 380
Study 27826183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg
Number of subjects: 35
Study 27826183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad 1,600 mg (supratherapeutic dose)
Number of subjects: 35
Study 27826183 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 35
Study 27826183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 24641639 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided periclavicular plexus blocks
Number of subjects: 6366
Study 24641639 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 6366
Study 22528707 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AADs) - metoprolol, propafenone, verapamil
Number of subjects: 84
Study 22528707 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AADs) - responders
Number of subjects: 84
Study 22528707 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFCA)
Number of subjects: 84
Study 22528707 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AADs) - long-term follow-up
Number of subjects: 84
Study 20233135 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred invasive treatment (balloon angioplasty or coronary bypass surgery)
Number of subjects: 751
Study 20233135 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 751
Study 20233135 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred invasive treatment
Number of subjects: 751
Study 16929241 — intervention group
Group type: EXPERIMENTAL
Intervention: Soymilk intervention (one serving)
Number of subjects: 43
Study 16929241 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no intervention)
Number of subjects: 43
Study 16380891 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cup replacement using the orthopilot navigation system
Number of subjects: 100
Study 16380891 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumented cup replacement
Number of subjects: 100
Study 11850523 — intervention group
Group type: EXPERIMENTAL
Intervention: Target velocity of 10-40 deg x s(‐1) with an ISI of 2.4 s
Number of subjects: 0
Study 11850523 — intervention group
Group type: EXPERIMENTAL
Intervention: Target velocity constant at 40 deg x s(‐1) with ISI varying from 0.48-3.74 s
Number of subjects: 0
Study 11850523 — intervention group
Group type: COMPARATOR
Intervention: Predictive responses compared with responses to randomised presentation
Number of subjects: 0
Study 9797801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampatrilat (50 mg, 100 mg, 200 mg)
Number of subjects: 124
Study 9797801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg)
Number of subjects: 124
Study 9797801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampatrilat
Number of subjects: 124
Study 9797801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 124
Study 9797801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 7706943 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/day)
Number of subjects: 4
Study 7706943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 2624612 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine (generic preparation P)
Number of subjects: 12
Study 2624612 — intervention group
Group type: COMPARATOR
Intervention: 10 mg nifedipine (reference preparation R)
Number of subjects: 12
Study 188622 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste W (calcium phosphate, sodium laurylsulfate, sodium sulforicinoleate)
Number of subjects: 53
Study 188622 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste X
Number of subjects: 53
Study 188622 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste Y
Number of subjects: 53
Study 188622 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste Z
Number of subjects: 53
Study 188622 — intervention group
Group type: COMPARATOR
Intervention: Placebo paste V
Number of subjects: 53
Study 30647445 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose guided by pharmacogenetics (LDG)
Number of subjects: 0
Study 30647445 — intervention group
Group type: COMPARATOR
Intervention: Maintenance dose (MDG)
Number of subjects: 0
Study 30647445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 28670721 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Elderly group (age >80 years)
Number of subjects: 580
Study 28670721 — intervention group
Group type: COMPARATOR
Intervention: Elderly group (age 75-80 years)
Number of subjects: 580
Study 26098993 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Number of subjects: 516
Study 26098993 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon/ribavirin
Number of subjects: 516
Study 26098993 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of HCV infection
Number of subjects: 516
Study 26098993 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNL4 genotype
Number of subjects: 516
Study 26098993 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HCV RNA <400,000 IU/mL
Number of subjects: 516
Study 26098993 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥40 years
Number of subjects: 516
Study 23474089 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 20
Study 23474089 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil
Number of subjects: 20
Study 21685340 — intervention group
Group type: EXPERIMENTAL
Intervention: TF (WHO simplified criteria grades of follicular trachoma)
Number of subjects: 2111
Study 21685340 — intervention group
Group type: EXPERIMENTAL
Intervention: TI (WHO simplified criteria grades of intense trachomatous inflammation)
Number of subjects: 2111
Study 21685340 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR (Polymerase Chain Reaction)
Number of subjects: 2111
Study 19212856 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Number of subjects: 100
Study 19212856 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 100
Study 16452738 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative infiltration mixture of local anesthetic and self-administered morphine
Number of subjects: 42
Study 16452738 — intervention group
Group type: COMPARATOR
Intervention: Self-administered morphine only (Control)
Number of subjects: 42
Study 15128706 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive community intervention
Number of subjects: 0
Study 15128706 — intervention group
Group type: EXPERIMENTAL
Intervention: Problems identified and their assumed causes
Number of subjects: 0
Study 11166665 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated intra-nasal anti-influenza vaccine
Number of subjects: 274
Study 11166665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 10783117 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir
Number of subjects: 30
Study 10783117 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir, zidovudine, and lamivudine
Number of subjects: 30
Study 10783117 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 8938911 — intervention group
Group type: COMPARATOR
Intervention: Placebo washout period
Number of subjects: 0
Study 8938911 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antipsychotic treatment
Number of subjects: 0
Study 1726005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 131
Study 1726005 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine SR
Number of subjects: 131
Study 1726005 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 131
Study 1726005 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 131
Study 1726005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 2 mg
Number of subjects: 131
Study 1726005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg
Number of subjects: 131
Study 6217951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) followed by metaproterenol (Met)
Number of subjects: 10
Study 6217951 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (IB) alone
Number of subjects: 10
Study 6217951 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol (Met) alone
Number of subjects: 10
Study 6217951 — intervention group
Group type: COMPARATOR
Intervention: Two consecutive inhalations of Met
Number of subjects: 10
Study 6217951 — intervention group
Group type: COMPARATOR
Intervention: Met followed by IB
Number of subjects: 10
Study 30668281 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate 0.2 g/kg BM (SBC2)
Number of subjects: 14
Study 30668281 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate 0.3 g/kg BM (SBC3)
Number of subjects: 14
Study 30668281 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (SBC2 and SBC3)
Number of subjects: 14
Study 30668281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 14
Study 30668281 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 14
Study 29976736 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography scans (CT scans)
Number of subjects: 1093
Study 29976736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative red bone marrow dose from CT scans
Number of subjects: 1093
Study 29976736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CT scans)
Number of subjects: 1093
Study 26689864 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin (80 mg/m(2)) and paclitaxel (200 mg/m(2)) followed by concurrent chemoradiotherapy (66 Gy in 33 fractions, cisplatin 80 mg/m(2) days 1, 29 and 57, vinorelbine 15 mg/m(2) days 1, 8, 29, 36, 57 and 64)
Number of subjects: 127
Study 26689864 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy followed by two cycles of cisplatin and paclitaxel
Number of subjects: 127
Study 24769888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of G-CSF-mobilized BMSCs
Number of subjects: 9
Study 24769888 — intervention group
Group type: COMPARATOR
Intervention: Control (serum)
Number of subjects: 9
Study 22318279 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (250 mg orally twice daily for 3 days)
Number of subjects: 300
Study 22318279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime (100 mg orally twice daily for 3 days)
Number of subjects: 300
Study 20667681 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 0
Study 20667681 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17440210 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers for the prison study
Number of subjects: 0
Study 17440210 — intervention group
Group type: COMPARATOR
Intervention: Control group (psychological study without prison life context)
Number of subjects: 0
Study 15699479 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 302
Study 15699479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 15699479 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (subgroup with life expectancy of 6 months or more)
Number of subjects: 302
Study 15699479 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subgroup with life expectancy of 6 months or more)
Number of subjects: 302
Study 15699479 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (subgroup with shorter life expectancy)
Number of subjects: 302
Study 15699479 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subgroup with shorter life expectancy)
Number of subjects: 302
Study 11815403 — intervention group
Group type: EXPERIMENTAL
Intervention: First-class mail
Number of subjects: 4999
Study 11815403 — intervention group
Group type: COMPARATOR
Intervention: Bulk mail
Number of subjects: 4999
Study 11815403 — intervention group
Group type: EXPERIMENTAL
Intervention: Including invitation letter
Number of subjects: 4999
Study 11815403 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment via mass mailings
Number of subjects: 4999
Study 9831138 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanoplasty type II with ionomeric cement
Number of subjects: 45
Study 9831138 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanoplasty type II with titanium-gold-angle prosthesis
Number of subjects: 45
Study 9831138 — intervention group
Group type: COMPARATOR
Intervention: Incus interposition
Number of subjects: 45
Study 7664508 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 20
Study 7664508 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 20
Study 7664508 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 20
Study 7664508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7664508 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg
Number of subjects: 20
Study 2502734 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium mupirocin 2% nasal ointment
Number of subjects: 34
Study 2502734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30814387 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis with lavage alone (A-group, n = 17)
Number of subjects: 40
Study 30814387 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis with lavage and hyaluronic acid injection (AS-group, n = 20)
Number of subjects: 40
Study 30814387 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 40
Study 26912531 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct instruction of MDI technique from a pharmacist
Number of subjects: 72
Study 26912531 — intervention group
Group type: COMPARATOR
Intervention: Reading a metered dose inhaler (MDI) package insert pamphlet
Number of subjects: 72
Study 26912531 — intervention group
Group type: COMPARATOR
Intervention: Watching a CDC video demonstrating MDI technique
Number of subjects: 72
Study 26912531 — intervention group
Group type: COMPARATOR
Intervention: Watching a YouTube video demonstrating MDI technique
Number of subjects: 72
Study 26409153 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-step time-lapse medium (G-TL)
Number of subjects: 128
Study 26409153 — intervention group
Group type: COMPARATOR
Intervention: Sequential media (G-1/G-2)
Number of subjects: 128
Study 23069838 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 with insulin
Number of subjects: 5
Study 23069838 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 with saline
Number of subjects: 5
Study 23069838 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 with vitamin C
Number of subjects: 5
Study 23069838 — intervention group
Group type: COMPARATOR
Intervention: GLP-1(9-36) during hyperinsulinemia
Number of subjects: 5
Study 23069838 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 5
Study 21596077 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 (1 ×)
Number of subjects: 443
Study 21596077 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7+PCV9 (2 ×)
Number of subjects: 443
Study 21596077 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × PCV7 + 2 × PCV9 (4 ×)
Number of subjects: 443
Study 21596077 — intervention group
Group type: COMPARATOR
Intervention: PPV (Control)
Number of subjects: 443
Study 19834342 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 8945
Study 19834342 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based treatment
Number of subjects: 8945
Study 16938694 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the number of associates studied
Number of subjects: 0
Study 16938694 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing backward associative strength
Number of subjects: 0
Study 16938694 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing study item presentation frequency
Number of subjects: 0
Study 16938694 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing study time
Number of subjects: 0
Study 15239094 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2b (1.5 microg/kg per week) and ribavirin (1000‐1200 mg/day) for 24 or 48 weeks depending on HCV genotype
Number of subjects: 100
Study 15239094 — intervention group
Group type: COMPARATOR
Intervention: Control group (no opioid maintenance)
Number of subjects: 100
Study 11288040 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 116
Study 11288040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 116
Study 11288040 — intervention group
Group type: COMPARATOR
Intervention: Control (wild-type allele)
Number of subjects: 116
Study 11288040 — intervention group
Group type: COMPARATOR
Intervention: Control (defective allele)
Number of subjects: 116
Study 11288040 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and Bezafibrate
Number of subjects: 116
Study 9303339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg b.i.d.) for 4 weeks
Number of subjects: 22
Study 9303339 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (PSL, 5-15 mg/day)
Number of subjects: 22
Study 8287653 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load of 10 cm H2O
Number of subjects: 7
Study 8287653 — intervention group
Group type: COMPARATOR
Intervention: Free breathing
Number of subjects: 7
Study 8287653 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic rebreathing
Number of subjects: 7
Study 3327703 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 200 micrograms
Number of subjects: 10
Study 3327703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31248973 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-melphalan-prednisone (VMP)
Number of subjects: 474
Study 31248973 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lenalidomide-dexamethasone (Rd-R)
Number of subjects: 474
Study 29396374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg twice daily for 24 months
Number of subjects: 113
Study 29396374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 27501597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.1 mg orally
Number of subjects: 165
Study 27501597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral corn starch)
Number of subjects: 165
Study 25749406 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of Negative Reviews
Number of subjects: 500
Study 25749406 — intervention group
Group type: EXPERIMENTAL
Intervention: Position of Negative Reviews
Number of subjects: 500
Study 25749406 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Elaboration
Number of subjects: 500
Study 23768747 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir (800 mg three times per day) plus peginterferon (1.5 μg/kg per week) and ribavirin (600-1400 mg per day) for 44 weeks
Number of subjects: 99
Study 23768747 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus peginterferon (1.5 μg/kg per week) and ribavirin (600-1400 mg per day) for 44 weeks
Number of subjects: 99
Study 23768747 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir (800 mg three times per day) plus peginterferon-ribavirin
Number of subjects: 99
Study 23768747 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus peginterferon-ribavirin
Number of subjects: 99
Study 23768747 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir plus peginterferon-ribavirin
Number of subjects: 99
Study 20870230 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling through oral presentations on menopause and HT (n=64)
Number of subjects: 125
Study 20870230 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=63)
Number of subjects: 125
Study 18270769 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine infusion at the beginning of LC plus normal saline infusion at the end (Group B)
Number of subjects: 120
Study 18270769 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine infusion at the beginning of LC (Group A)
Number of subjects: 120
Study 18270769 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group F)
Number of subjects: 120
Study 16855196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention emphasizing comparison of experienced outcomes with expectation of ideal outcomes
Number of subjects: 331
Study 16855196 — intervention group
Group type: COMPARATOR
Intervention: Cognitive intervention emphasizing comparison of experienced outcomes with pretreatment status
Number of subjects: 331
Study 12529346 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention promoting a low-fat diet
Number of subjects: 286
Study 12529346 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 286
Study 10423655 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg intravenous dolasetron
Number of subjects: 21
Study 10423655 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg/kg intravenous dolasetron
Number of subjects: 21
Study 8899321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain
Number of subjects: 15
Study 8899321 — intervention group
Group type: COMPARATOR
Intervention: Control (no Ukrain)
Number of subjects: 15
Study 1897345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg.kg‐1 followed by suxamethonium 1.5 mg.kg‐1 in E1uE1a patients
Number of subjects: 43
Study 1897345 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium 1.5 mg.kg‐1 without pretreatment in E1uE1a patients
Number of subjects: 43
Study 1897345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg.kg‐1 followed by suxamethonium 1.5 mg.kg‐1 in E1uE1u patients
Number of subjects: 43
Study 1897345 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium injection
Number of subjects: 43
Study 6407503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100-300 mg daily)
Number of subjects: 73